Werewolf Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 47
- Market Cap
- $99.6M
- Website
- http://www.werewolftx.com
- Introduction
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Conditions
- Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
- Interventions
- Drug: WTX-330
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Werewolf Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05678998
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Emory Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorAdvanced Solid Tumor
- Interventions
- Drug: WTX-124Drug: pembrolizumab
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Werewolf Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05479812
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States